The Partial M<sub>1</sub> Muscarinic Cholinergic Receptor Agonist, CDD-0102A, Differentially Modulates Glutamate Efflux in Striatal Subregions during Stereotyped Motor Behavior in the BTBR Mouse Model of Autism.
Journal Information
Full Title: ACS Chem Neurosci
Abbreviation: ACS Chem Neurosci
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"all analyses for glutamate concentrations raw glutamate data and behavioral data are available at doi: 10 6084/m9 figshare c 6597052 ."
"The authors declare the following competing financial interest(s): Dr. William S. Messer holds patents for the use of muscarinic agonists in the treatment of neurological disorders and is the founder and president of Psyneurgy Pharmaceuticals LLC. Dr. Michael Ragozzino holds a patent for use of muscarinic agonists in the treatment of neurological disorders."
"We thank Roberto Ocampo for technical assistance in carrying out the experiments. We thank Dr. Mitchell F. Roitman for suggestions on data analyses. This research was supported by the National Institute of Health (Grant HD084953)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025